PLTR133.99+0.19%
PLTR · US
1y range: 128.06 → 160.84 · as of 2026-05-15
AI digest — today
Palantir behaalde in Q1 85% omzetgroei en verhoogde full-year guidance met ~$500M, gedreven door recordgroei in US commercial (133%). Vandaag: NHS England verleent Palantir-contractoren onbeperkte toegang tot patiëntgegevens voor flagship data platform — significant regulatory win in UK public sector.
Generated 2026-05-11 20:11
Weekly thesis
Palantir accelereert op AI-platform adoptie en government contracten, maar 105x P/E en insider selling vormen waarschuwingssignalen op korte termijn.
Bull case
- Q1 2026: 85% omzetgroei + full-year guidance +$500M — structurele AI-platform traction in commercial (133% US commercial groei) en government - $300M USDA Blanket Purchase Agreement + NHS England regulatory win = TAM-expansie buiten defensie naar agrarische en UK public sector - Vier opeenvolgende EPS-beats (Q2-Q4 2025, Q1 2026) met gemiddeld +10-15% outperformance vs consensus — earnings momentum is echt - Analyst consensus: 26 buy/strong buy vs 2 sell; mediane price target $200 impliceert 10-15% upside, maar 85% upside genoemd door enkele analisten - Foundry/AIP adoptie accelereert; Vanyar consultancy launch toont confidence in APAC/Middle East enterprise expansion
Bear case
- 105x P/E is extreem; laat nul ruimte voor groei-vertraging of margin-compressie — één teleurstelling = 15-20% correctie - Insider selling-signaal (hoewel Thiel's Buenos Aires aankoop ook diversificatie kan zijn) + 20% YTD 2026 daling suggereert momentum-fragility - Commercial backlog en RPO-momentum zijn 'monitoring'-items — geen concrete groei-bewijzen voorbij Q1; volgende quarters kritisch - Analyst consensus verdeeld: 10 hold + 2 sell vs 26 buy — geen unanimiteit; DA Davidson neutral op $180 suggereert beperkter upside dan bulls claimen - Government contracts zijn lumpy en contract-afhankelijk; USDA-deal is groot, maar herhaalbaarheid onzeker
Recent material news
- Germany opts for French software for intelligence service over American Palantir2026-05-17T15:01
- Britain's NHS to grant Palantir contractors 'unlimited access' to patient data, FT reports2026-05-11T00:10
- Dan Ives Can’t Make It Any Clearer: Palantir Stock Is Still a ‘Golden Goose’ Despite Q1 Earnings Fears2026-05-10T14:00
- Palantir's Pullback Hides A Massive Transformation2026-05-09T09:16
- Rackspace Technology Q1 Earnings Call Highlights2026-05-09T01:06
- Palantir Just Crushed Earnings. So Why Is the Stock Down?2026-05-08T20:55
- After Palantir's Impressive Q1 Earnings Report, This Remains the Biggest Issue With the Stock2026-05-08T07:31
- Innodata Q1 Earnings Call Highlights2026-05-08T04:06
Want this depth on every stock you watch?
ThickerPeek writes a daily AI digest on 165+ stocks, weekly theses, earnings briefings, and alerts — for €19/mo. Free tier available.
Not investment advice. ThickerPeek is a research tool. AI-written content is informational, not a buy/sell recommendation. Investment decisions are your own responsibility.